The link between impulsivity and dopamine

Phase 1

Completed

• Conditions: Impulse control disorders in Parkinson's disease patients taking dopaminergic medication; Neurological - Parkinson's disease

• Registration Number: ACTRN12614000046606
• Lead Sponsor: Professor Winston Byblow

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-01-17
• Study Completion: 2015-12-31
• Last Update Posted: 7 December 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 33

Inclusion Criteria

Between 40 and 75 years of age.
No neurological disease or disorder.
Normal or corrected to normal vision.

Exclusion Criteria

Cognitive impairment (MoCA score below 26); unable to provide informed consent; any contraindications to the medications or placebo. Contraindications include: a known hypersensitivity to ropinirole, domperidone, or any of the excipients; history of acute or chronic psychiatric disorder; history of severe cardiac, hepatic or renal disease; history of severe systemic disease; history of severe dizziness or fainting; a prolactin-releasing pituitary tumour; currently breast feeding; current tobacco smoking or nicotine patch; lactose intolerance; glucose/galactose malabsorption and any medications which may interact with ropinirole or domperidone, or themselves cause drowsiness.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Stop signal reaction time in the Response Inhibition Task (motor impulse control).<br>[1-2 hours after ropinirole administration.];Number of responses in the Balloon Analogue Risk Task (cognitive impulse control).[1-2 hours after ropinirole administration.]

Secondary Outcome Measures

Name	Time	Method
EMG profile of responses in Response Inhibition Task.[1-2 hours after ropinirole administration.]